Takeru Wakatsuki
Ariake, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 93 publications
Proteinuria as the cause of early dose modification in Japanese patients with metastatic colorectal cancer treated with fruquintinib: a multicenter real-world study.
Journal: International journal of clinical oncology
Published: May 28, 2026
ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer.
Journal: Cancer research communications
Published: December 17, 2025
Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer.
Journal: Targeted oncology
Published: November 17, 2025
Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience.
Journal: Journal of cancer research and clinical oncology
Published: November 16, 2025
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer.
Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Published: November 08, 2025
Increased treatment options and improved survival in real-world patients with HER2-positive advanced gastric cancer from 2011 to 2023.
Journal: Therapeutic advances in gastroenterology
Published: October 13, 2025
Glucocorticoids rarely required in granulocyte colony-stimulating factor-associated large-vessel vasculitis: Japanese cancer centre cohort.
Journal: Rheumatology (Oxford, England)
Published: October 08, 2025
High-dose dexamethasone and prolonged infusion time prevent oxaliplatin-related hypersensitivity reactions in patients with metastatic colorectal cancer.
Journal: International journal of clinical oncology
Published: August 13, 2025
Peripheral SNCA+ cells as a poor prognostic factor for nivolumab therapy in advanced gastric cancer.
Peripheral SNCA+ cells as a poor prognostic factor for nivolumab therapy in advanced gastric cancer.
Journal: Discover oncology
Published: July 24, 2025
Usefulness of pharmacy outpatient clinic follow-up for maintaining relative dose intensity in patients on adjuvant CAPOX chemotherapy for gastric cancer.
Journal: Molecular and clinical oncology
Published: July 09, 2025
IL33-ST2 axis is a predictive biomarker for anti-PD1 therapeutic efficacy in advanced gastric cancer.
Journal: Journal of translational medicine
Published: July 01, 2025
Last Updated: 09/26/2026